Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity drug Zepbound from the list of medicines it covers for reimbursement ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Bucks County, Pa. has initiated legal proceedings against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated effort to inflate ...

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly revealed in a first-quarter earnings report last week that it now has a 53% ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly Downplays CVS Move to Drop Zepbound Coverage, Shares Plunge By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's ...